Cortexyme Competitors

Beam Therapeutics (NASDAQ:BEAM) and Cortexyme (NASDAQ:CRTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Profitability

This table compares Beam Therapeutics and Cortexyme's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Beam Therapeutics and Cortexyme's revenue, earnings per share (EPS) and valuation.

Cortexyme has lower revenue, but higher earnings than Beam Therapeutics. Cortexyme is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for Beam Therapeutics and Cortexyme, as provided by MarketBeat.

Beam Therapeutics currently has a consensus target price of $96.00, suggesting a potential upside of 30.63%. Cortexyme has a consensus target price of $50.00, suggesting a potential upside of 37.48%. Given Cortexyme's higher possible upside, analysts clearly believe Cortexyme is more favorable than Beam Therapeutics.

Insider & Institutional Ownership

49.8% of Beam Therapeutics shares are held by institutional investors. Comparatively, 55.5% of Cortexyme shares are held by institutional investors. 0.7% of Beam Therapeutics shares are held by company insiders. Comparatively, 19.8% of Cortexyme shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Cortexyme beats Beam Therapeutics on 9 of the 12 factors compared between the two stocks.

Relay Therapeutics (NASDAQ:RLAY) and Cortexyme (NASDAQ:CRTX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Earnings & Valuation

This table compares Relay Therapeutics and Cortexyme's revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Relay Therapeutics and Cortexyme, as provided by MarketBeat.com.

Relay Therapeutics presently has a consensus target price of $57.40, suggesting a potential upside of 43.54%. Cortexyme has a consensus target price of $50.00, suggesting a potential upside of 37.48%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Relay Therapeutics is more favorable than Cortexyme.

Profitability

This table compares Relay Therapeutics and Cortexyme's net margins, return on equity and return on assets.

Insider and Institutional Ownership

98.4% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 55.5% of Cortexyme shares are owned by institutional investors. 19.8% of Cortexyme shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Relay Therapeutics beats Cortexyme on 6 of the 7 factors compared between the two stocks.

Cortexyme (NASDAQ:CRTX) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for Cortexyme and SpringWorks Therapeutics, as provided by MarketBeat.

Cortexyme presently has a consensus price target of $50.00, suggesting a potential upside of 37.48%. SpringWorks Therapeutics has a consensus price target of $91.00, suggesting a potential upside of 31.31%. Given Cortexyme's higher possible upside, research analysts plainly believe Cortexyme is more favorable than SpringWorks Therapeutics.

Insider and Institutional Ownership

55.5% of Cortexyme shares are owned by institutional investors. Comparatively, 76.3% of SpringWorks Therapeutics shares are owned by institutional investors. 19.8% of Cortexyme shares are owned by insiders. Comparatively, 51.2% of SpringWorks Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Cortexyme has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.

Valuation and Earnings

This table compares Cortexyme and SpringWorks Therapeutics' gross revenue, earnings per share and valuation.

SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Cortexyme, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cortexyme and SpringWorks Therapeutics' net margins, return on equity and return on assets.

Summary

Cortexyme beats SpringWorks Therapeutics on 6 of the 11 factors compared between the two stocks.

Revolution Medicines (NASDAQ:RVMD) and Cortexyme (NASDAQ:CRTX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Profitability

This table compares Revolution Medicines and Cortexyme's net margins, return on equity and return on assets.

Institutional and Insider Ownership

85.8% of Revolution Medicines shares are owned by institutional investors. Comparatively, 55.5% of Cortexyme shares are owned by institutional investors. 19.8% of Cortexyme shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Revolution Medicines and Cortexyme, as provided by MarketBeat.com.

Revolution Medicines presently has a consensus price target of $50.75, suggesting a potential upside of 19.55%. Cortexyme has a consensus price target of $50.00, suggesting a potential upside of 37.48%. Given Cortexyme's higher possible upside, analysts clearly believe Cortexyme is more favorable than Revolution Medicines.

Earnings & Valuation

This table compares Revolution Medicines and Cortexyme's gross revenue, earnings per share and valuation.

Cortexyme has lower revenue, but higher earnings than Revolution Medicines.

Summary

Revolution Medicines beats Cortexyme on 5 of the 9 factors compared between the two stocks.

Cortexyme (NASDAQ:CRTX) and NantKwest (NASDAQ:NK) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Valuation & Earnings

This table compares Cortexyme and NantKwest's top-line revenue, earnings per share (EPS) and valuation.

Cortexyme has higher earnings, but lower revenue than NantKwest. NantKwest is trading at a lower price-to-earnings ratio than Cortexyme, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Cortexyme and NantKwest, as provided by MarketBeat.

Cortexyme presently has a consensus price target of $50.00, suggesting a potential upside of 37.48%. NantKwest has a consensus price target of $18.00, suggesting a potential downside of 30.10%. Given Cortexyme's higher probable upside, equities research analysts clearly believe Cortexyme is more favorable than NantKwest.

Insider & Institutional Ownership

55.5% of Cortexyme shares are owned by institutional investors. Comparatively, 9.4% of NantKwest shares are owned by institutional investors. 19.8% of Cortexyme shares are owned by insiders. Comparatively, 71.7% of NantKwest shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Cortexyme has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, NantKwest has a beta of 2.61, suggesting that its stock price is 161% more volatile than the S&P 500.

Profitability

This table compares Cortexyme and NantKwest's net margins, return on equity and return on assets.

Summary

Cortexyme beats NantKwest on 8 of the 13 factors compared between the two stocks.

Editas Medicine (NASDAQ:EDIT) and Cortexyme (NASDAQ:CRTX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Institutional and Insider Ownership

87.5% of Editas Medicine shares are held by institutional investors. Comparatively, 55.5% of Cortexyme shares are held by institutional investors. 0.9% of Editas Medicine shares are held by company insiders. Comparatively, 19.8% of Cortexyme shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Editas Medicine and Cortexyme's revenue, earnings per share (EPS) and valuation.

Cortexyme has lower revenue, but higher earnings than Editas Medicine. Cortexyme is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Editas Medicine and Cortexyme's net margins, return on equity and return on assets.

Volatility & Risk

Editas Medicine has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500. Comparatively, Cortexyme has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Editas Medicine and Cortexyme, as reported by MarketBeat.

Editas Medicine presently has a consensus target price of $49.2222, suggesting a potential upside of 21.96%. Cortexyme has a consensus target price of $50.00, suggesting a potential upside of 37.48%. Given Cortexyme's stronger consensus rating and higher possible upside, analysts clearly believe Cortexyme is more favorable than Editas Medicine.

Summary

Cortexyme beats Editas Medicine on 8 of the 13 factors compared between the two stocks.